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Proof of principle: The effect of antimuscarinics on bladder
filling sensations in healthy subjects-A placebo controlled double
blind investigation using 4 and 8 mg tolterodine extended release
Abstract
AIMS: There is evidence that antimuscarinic drugs have depressant influence not only on bladder
muscle activity, but also on bladder sensations. The aim of this study was to evaluate the effect of a
single dose tolterodine extended release (ER) 4 and 8 mg on bladder sensations during filling
cystometry. METHODS: After approval of the local ethics committee, 30 healthy female subjects (23.7
+/- 2.3 years) were included and randomly assigned to three groups: (A) placebo, (B) tolterodine ER 4
mg, and (C) tolterodine ER 8 mg in a double blind manner. Measurements were performed at baseline
and 4 hr postmedication in each group, consisting of: (1) Filling cystometry with 25 ml/min at which
subjects had to indicate first sensation of filling (FSF), first desire to void (FDV), and strong desire to
void (SDV). (2) Uroflowmetry and ultrasound control for residual urine. RESULTS: In the placebo
group, filling volumes at FDV and SDV decreased significantly posttreatment. This effect could not be
observed for the tolterodine 8 mg group and only at SDV in the 4 mg group. No significant difference
between groups was found regarding uroflowmetry parameters and postvoid residual volume.
CONCLUSIONS: No increase of filling volumes in healthy subjects could be observed with tolterodine.
However, the results suggest that tolterodine is able to alleviate irritation caused by repeated
catheterization and cystometry. There was no significant influence of tolterodine ER 4 or 8 mg on
voiding function.
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Abstract: 
Aims: 
There is evidence that antimuscarinic drugs have depressant influence not only on 
bladder muscle activity, but also on bladder sensations. The aim of this study was to 
evaluate the effect of a single dose tolterodine extended release (ER) 4 and 8 mg on 
bladder sensations during filling cystometry. 
 
Methods: 
After approval of the local ethics committee, 30 healthy female subjects (23.9 2.3 
years) were included and randomly assigned to 3 groups: A) placebo, B) tolterodine 
ER 4mg and C) tolterodine ER 8mg in a double blind manner. 
Measurements were performed at baseline and 4 hours post medication in each group, 
consisting of: 1) Filling cystometry with 25ml/min. at which subjects had to indicate 
first sensation of filling (FSF), first desire to void (FDV) and strong desire to void 
(SDV). 2) Uroflowmetry and ultrasound control for residual urine. 
 
Results: 
In the placebo group, filling volumes at FDV and SDV decreased significantly post 
treatment. This effect could not be observed for the tolterodine 8 mg group and only 
at SDV in the 4 mg group. 
No significant difference between groups was found regarding uroflowmetry 
parameters and post void residual volume. 
 
Conclusions: 
No increase of filling volumes in healthy subjects could be observed with tolterodine. 
However, the results suggest that tolterodine is able to alleviate irritation caused by 
repeated catheterisation and cystometry. There was no significant influence of 
tolterodine ER 4 or 8 mg on voiding function. 
Introduction: 
The main characteristics of the overactive bladder (OAB) are urgency with or without 
incontinence and frequency (Abrams et al., 2003). Urgency as the most bothersome symptom 
is described as a sudden, compelling desire to void, which is difficult to defer and often forces 
the patients to rush to the rest room. If urgency is associated with incontinence, because the 
patient can not reach the toilette in time, the problem becomes even more bothersome and the 
quality of life is severely reduced (Starkman and Dmochowski, 2008). 
There are several antimuscarinic drugs on the market to treat this condition. The well known 
mechanism of action of these drugs is to competitively block the acetylcholine (ACh) 
receptors (M2, M3) on the detrusor muscle and therefore reduce detrusor overactivity (DO) 
(Andersson and Yoshida, 2003). However, not all patients suffering from OAB show a DO in 
urodynamics. Nevertheless, those patients experience a benefit from antimuscarinic treatment, 
by means of reduced urgency and reduced frequency (Nabi et al., 2006). Especially the 
warning time, defined as the time from the first sensation of urgency to voluntary micturition 
or incontinence, is significantly increased in OAB patients taking antimuscarinics (Cardozo 
and Dixon, 2005). This clinical observation raises the possibility that there might be 
additional mechanisms of action of antimuscarinics. Antimuscarinics are usually competitive 
antagonists and act mainly during the storage phase, when only little or no parasympathetic 
outflow to the detrusor exists (Andersson and Yoshida, 2003). Recent immunohistological 
studies showed that the muscarinic receptors M2 and M3 could be found not only on detrusor 
muscle cells, but also on bladder afferent nerve endings, the interstitial cells and the 
urothelium itself and animal studies revealed a depressant influence of antimuscarinics like 
tolterodine on bladder afferent nerves (Abrams et al., 2006; Andersson and Yoshida, 2003; De 
Laet et al., 2006; Hedlund et al., 2007; Kim et al., 2005; Yokoyama et al., 2005). 
Summarizing these findings, an effect of antimuscarinic drugs on the afferent pathways can 
be strongly assumed. 
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However, it is not clear, if this effect on the afferent pathway is mediated by a reversal or 
alleviation of pathophysiological mechanisms, as some studies might suggest, or simply on an 
effect on the normal sensory pathways. 
 
Therefore, we investigated in healthy subjects the effect of 4 and 8 mg tolterodine on bladder 
filling sensations. Our hypothesis was that tolterodine ER has an effect on the normal sensory 
pathway and will, in contrast to placebo, elevate the perception threshold for the different 
filling sensations, which means higher bladder volumes at first sensation of filling (FSF), first 
desire to void (FDV) and strong desire to void (SDV). We expected a more pronounced effect 
for the 8 mg group compared to the 4 mg group. 
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Subjects & Methods: 
After approval of the local ethics committee, a volunteer sample of healthy female subjects 
was recruited. 
Inclusion criteria: healthy female subjects aged 18 to 30 years. Exclusion criteria: Any known 
past or current illness of the upper and lower urinary tract or the female genital tract 
(including OAB and any form of incontinence or other lower urinary tract symptoms), 
pregnant or breastfeeding subjects, any current general medical treatment or intervention 
(except seasonal allergies, routine medical examinations or check-ups and preventive 
consultations – but examinations or check-ups should be performed not shorter than 3 days 
before the assigned study day), any regular medication (except oral contraceptives, low-dose 
antiallergic drugs for the treatment of seasonal allergies, any occasionally taken low dose non 
steroidal anti-inflammatory drugs (NSAIDs) or other over the counter pain killers are allowed 
but not on the examination day), any medical condition that interferes or is a contraindication 
for the use of tolterodine (e.g. glaucoma, myasthenia gravis, liver or renal insufficiency, 
allergy against anticholinergics), any neurological or psychiatric condition, any condition that 
suggests that the subject does not feel well or will not be able to complete the study 
examinations. 
After written informed consent was obtained, all subjects were randomly assigned to 3 
groups: A) placebo, B) tolterodine ER 4 mg and C) tolterodine ER 8 mg in a double blind 
manner. Each subject was assigned to a specific test date, on which the subject was not 
allowed to drink before the study investigation (except a small glass of water). Prior to the 
investigation each subject was checked for pregnancy and urinary tract infection, using urine 
dip stick tests.  
The investigation consisted of a measurement at baseline and 4 hours post medication, when 
maximum plasma concentrations can be expected (Olsson and Szamosi, 2001b). Each 
measurement was performed identically in each group according to the following protocol: 1) 
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Subjects were positioned comfortably and supine on an urodynamic examination table, 
wearing ear plugs to avoid possible distraction. 2) An 8 Fr transurethral microtip filling 
catheter (UniTip, Unisensor AG, Attikon, Switzerland) was inserted and correct positioning 
of the catheter was controlled by urethral pressure and fluoroscopy. Filling cystometry using 
body warm saline was performed with 25ml/min and subjects had to indicate FSF, FDV and 
SDV by pressing a push button. All 3 filling sensations were defined according to the ICS 
terminology and all definitions were explained comprehensibly to the subjects before the 
measurement (Abrams et al., 2003). The corresponding intravesical pressures and filling 
volumes were recorded. There was no interaction between subjects and investigator during the 
filling cystometry. The filling was stopped shortly after subjects indicated SDV. 3) Following 
cystometry, subjects were allowed to empty their bladder in an uroflowmetry-toilette, where 
maximum flow rate (Qmax), average flow rate (Qave) and voided volume was recorded. 
Finally, ultrasound control for post void residual urine (PVRV) was performed. 
During the break between the baseline and post medication measurement, the transurethral 
catheter was removed and subjects were allowed to dress and spend their break in the 
cafeteria, the relaxation room or the hospital park. 
A telephone follow up was performed 2-3 days after the investigation to check for any side 
effects. 
All bladder volumes are presented as corrected volumes according to the following formula: 
(voided volume + PVRV) / cystometric capacity at SDV. The resulting factor was multiplied 
with the cystometric volumes at FSF, FDV and SDV. 
A sample size calculation was performed based on the few, available literature references and 
own pilot investigations (Jonas et al., 1997; Rentzhog et al., 1998; Stahl et al., 1995). The 
alpha level was set at 5% and the power at 80%. A pairwise double-sided analysis within one 
group with an expected change for FDV of 50 ml in the tolterodine 4mg group and a standard 
deviation of 140 ml would require a sample size of 5 subjects. However, to compare between 
4 
groups with an estimated difference of 20% between placebo and tolterodine 4mg and a 
standard deviation of 14%, a sample size of at least 9 subjects would be necessary 
(http://www.quantitativeskills.com/sisa/). 
A statistical analysis of outcome parameters before and after treatment within each group was 
performed using the Wilcoxon signed ranks test in SPSS 14.0 (SPSS Inc. Headquarters, 233 
S. Wacker Drive, 11th floor, Chicago, Illinois 60606). 
Differences in outcome parameters between groups before and after treatment were 
statistically analysed using the Kruskal-Wallis test and Mann-Whitney U test (2-tailed) in 
SPSS 14.0. 
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Results: 
Thirty healthy female subjects (mean age: 23.7 2.3 years, mean BMI: 20.5 1.7 kg/m2) were 
included and equally randomized among the 3 groups (Table 1). 
As per our exclusion criteria, none of the subjects had OAB symptoms or incontinence. All 
subjects tolerated the measurements well and completed the whole investigation and follow 
up. However, catheterization and the SDV sensation were reported as rather uncomfortable 
but still easily tolerable. None of the subjects showed DO in the cystometries. 
Only minor side effects (e.g. tiredness, slight headache) were reported in single cases from all 
groups. 
At baseline, no significant difference between the three groups regarding age and BMI as well 
as for FSF, FDV, SDV, bladder compliance, Qmax, Qave and PVRV could be observed (Table 
1). Summarizing all 30 baseline measurements, subjects showed a mean (± SD) bladder 
volume of 152 ml (±88.8), 309 ml (±141.8), and 646.8 ml (±194.3) at FSF, FDV, and SDV 
respectively (Figure 1). 
Comparing the bladder volumes before and after treatment in each group for each filling 
sensation, no changes in filling volume could be observed at FSF in any group (Table 1, 
Figure 2). 
At FDV, a significant decrease in filling volumes was found in group A, comparing pre with 
post treatment cystometry. Groups B and C showed no significant change in filling volumes at 
FDV, although a tendency towards elevated filling volumes after treatment could be observed 
in group C (Table 1, Figure 3). Nevertheless, no significant differences between groups post 
treatment could be found at FDV. 
At SDV, group A showed again a significant decrease in filling volumes, comparing pre with 
post treatment cystometry (Table 1, Figure 4). This time, the decrease was even more 
pronounced as compared to at FDV. In group B, a significant decrease in filling volumes at 
SDV could be found as well. Group C showed no significant change in filling volumes at 
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SDV (Table 1, Figure 4). The comparison between groups post treatment showed significant 
lower bladder volumes at SDV in group A compared to group C (Figure 4). 
The intravesical pressure decreased significantly in the placebo group at FDV and SDV. No 
significant changes in intravesical pressure could be observed for the tolterodine groups. 
Regarding the comparison of intravesical pressure between groups, no significant difference 
could be found before or after treatment (Table 1). 
For bladder compliance, Qmax, Qave, and PVRV no significant differences were found before 
and after treatment within each group or between groups (Table 1). 
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Discussion: 
Our hypothesis was that a single dose of 4 and 8 mg tolterodine ER will elevate the perception 
threshold for bladder filling sensations. This effect was expected to be more pronounced with 
8 mg compared to 4 mg. 
Our results showed that all groups had equal or similar baseline values in all measured 
parameters. Comparing at first the baseline filling volumes of all groups (Fig. 1) with the 
literature, a great similarity with the results of the study from Wyndaele et al. can be observed 
(Wyndaele and De Wachter, 2002). This accordance demonstrates quite a good 
reproducibility of urodynamically measured filling sensations, bearing in mind that Wyndaele 
et al. investigated two different subject populations with an interval of 5 years and our results 
are even coming from a different site. 
Regarding the effect of tolterodine on the filling sensation, our hypothesis seems not correct 
and has to be rejected based on these data. 
Although there was no elevation of filling volumes due to tolterodine, despite the tendency in 
group C at FDV, there was a significant decrease in filling volumes in group A at FDV and 
SDV, which was not observed in group C. Group B ranged in an intermediate position with a 
decrease of filling volumes at SDV only. 
The remarkable decrease of filling volumes at SDV in the placebo group resulted in a highly 
significant difference between the placebo group and the tolterodine 8 mg group, in which 
filling volumes remained on the same level pre and post treatment (Figure 4). Likewise, the 
pVes showed a significant reduction in the placebo group at FDV and SDV. However, this 
effect on the pVes was not pronounced enough to show significant differences between 
groups. 
A possible explanation for the decreased filling volumes and pVes values in the placebo 
group during the second cystometry might be a sensitization of the lower urinary tract (LUT) 
in our female study population due to the repeated catheterisation and bladder filling, which 
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led to an increased sensibility. Bladder afferent firing and subsequently most likely also the 
perception of filling sensations is strongly related to the intravesical pressure (Habler et al., 
1993), which in turn is mainly affected by the intravesical volume in healthy non-OAB 
subjects. If there is sensitization or irritation of the LUT, less intravesical pressure and 
therefore less volume is probably necessary to cause afferent activity of Aδ-fibres and thus the 
sensation of FDV and SDV. During the second cystometry, subjects in the placebo group 
indicated sensations earlier, before pVes reached the threshold at which the subjects had 
indicated sensations during the baseline cystometry, i.e. the pressure threshold for perceiving 
filling sensations was lowered. As both, filling volume and pVes decreased, compliance 
remained more or less unchanged. 
In group B and even more in group C, although both groups were not significantly different, 
the sensitization seems to be alleviated by tolterodine, as pVes and filling volumes remained 
constant in both tolterodine groups. From this point of view, we of course can not argue that 
the LUT in the female subjects was still “normal” as it was in fact sensitized or irritated by the 
repeated catheterisation and filling. 
The few studies investigating the effect of repeated filling cystometries in healthy females 
reported conflicting results (Brostrom et al., 2002; Gupta et al., 2004; Mortensen et al., 2002; 
Sorensen et al., 1988). In the study of Mortensen et al., bladder volumes at FDV and SDV 
were significantly lower in the second compared to the first cystometry (Mortensen et al., 
2002). In an older study from Sörensen et al., bladder volumes at FDV and SDV were as well 
lower in the second cystometry (Sorensen et al., 1988). However, for SDV the finding was not 
significant. In contrast, the study of Bostrom et al. showed elevated bladder volumes at FDV 
in the second cystometry and constant volumes at SDV (Brostrom et al., 2002). A newer 
study by Gupta et al. showed a significant increase in FSF, FDV and voided volumes in the 
second compared to the first cystometry (Gupta et al., 2004). Nevertheless, there are two main 
differences between those studies and this study. First, all four previously mentioned studies 
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performed consecutive cystometries immediately succeeding each other, leaving the 
transurethral catheter in place. In our study, the catheter was removed after the first 
cystometry and replaced after 4 hours. A repeated catheterisation probably causes further 
irritation of the LUT. Secondly, the age range in the previously mentioned studies was very 
broad, ranging from 14 to 74 years, resulting in an inhomogeneous population of females 
previous to child birth, after one or more pregnancies and postmenopausal. In our study a 
homogeneous population of young females (20-28 years) without previous pregnancy was 
investigated. Age however has a considerable influence on LUT sensibility, which decreases 
with age (Kenton et al., 2007a; Kenton et al., 2007b; Kinn and Nilsson, 2005). Young women 
without previous childbirth have a more sensible urethra compared to elderly women or 
women with previous childbirth. 
We therefore strongly assume that the reduced volumes and pVes values at FDV and SDV 
during the second cystometry observed in the placebo group are related to LUT sensitization 
or irritation due to the repeated catherization and filling cystometry. As this could not be 
observed in the tolterodine 8 mg group, tolterodine seems to be able to reduce or prevent 
irritative sensations from the LUT. 
However, these findings do not suggest that a single dose tolterodine ER 4 or 8 mg has an 
influence on unaffected healthy bladder filling sensations or that it can significantly elevate 
the filling perception threshold beyond baseline in health subjects. 
There are only two open label, non-randomized, non-controlled single dose studies available, 
investigating the urodynamic effect of tolterodine in healthy subjects (Boy et al., 2007; Stahl 
et al., 1995). The first study by Stahl et al. was performed in 12 healthy males, who were in 
the same age range (21-29 years) as our female sample. Despite this, the major difference to 
our study was that 6.4 mg of the immediate release (IR) preparation were used. The results of 
this study showed that tolterodine significantly increased the volumes necessary to induce 
FSF and normal desire to void sensations but also significantly increased the PVRV and 
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significantly decreased Qmax (Stahl et al., 1995). The most plausible reason for the different 
findings in our and the study of Stahl et al. are the different pharmacokinetic properties of the 
two formulations IR and ER (Stahl et al., 1995). The once daily ER formulation of tolterodine 
4mg has indeed a similar area under the serum concentration-time curve from zero to 24 hours 
(AUC24) as the 2 mg twice daily IR formulation, but maximum serum concentration (Cmax) is 
significantly lower for ER, which might explain the lower rate of side effects like dry mouth 
or urinary retention, but also the lesser development of effects on the LUT at single dosing 
(Olsson and Szamosi, 2001b). 6.4 mg tolterodine IR is quite a high dose, which was 
specifically selected to secure an effect on the bladder (Stahl et al., 1995). However, this same 
effect on filling sensations could not be shown in our study even with 8 mg ER. 
The other study by Boy et al. showed no difference in filling volumes 2 h after oral 
administration of 4 mg tolterodine IR in 7 healthy females (Boy et al., 2007). Instead, a 
significant increase in bladder electrical perception threshold (EPT) was observed (Boy et al., 
2007). However, bladder EPTs and filling sensations are neither related to nor are they 
correlated with each other and are therefore hardly comparable (De Laet et al., 2005; De 
Wachter and Wyndaele, 2001). If the difference in findings between the study of Stahl et al. 
and Boy et al. is mainly related to the different dosage used (6.4 mg vs. 4 mg respectively), or 
if the time points of urodynamic measurement also play a crucial role (1 h and 5 h post dose 
vs. 2 h post dose respectively), remains unclear. It is however surprising, that the significant 
increase in filling volumes at normal desire to void in the study of Stahl et al. could be only 
detected in the 5 h post dose cystometry but not during the cystometry 1 h post dose, although 
the plasma level evaluation clearly indicated a mean Cmax at 1 h post dose (Stahl et al., 1995). 
In OAB, the storage phase is disturbed with urgency and frequency. The underlying 
pathomechanism might be neurogenic, myogenic and/or a resulting dysbalance/dysfunction of 
the biochemical interaction between the urothelium, neural pathways, interstitial cells and 
smooth muscle cells, which is still not completely understood. Nevertheless, dysregulation of 
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ACh release and muscarinic receptor expression, not only from and on the presynaptic nerve 
fibers, but also from and on the urothelium seems to play an important role in the 
pathogenesis of OAB (Abrams et al., 2006; Andersson, 2004; Andersson and Yoshida, 2003; 
de Groat, 2006). Antimuscarinics have shown to be beneficial in the therapy of OAB 
symptoms, most probably due to their influence on ACh-release and ACh-receptor binding 
(Abrams et al., 2006; Andersson, 2004). Although it is known that the main muscarinic input 
to the bladder occurs during the micturition phase, there is also ACh-release and ACh-
receptor expression during the storage phase, which might be abnormal in the case of OAB 
and would explain why OAB symptoms are susceptible to antimuscarinic treatment 
(Andersson, 2004; Andersson and Yoshida, 2003). In our experiment, repeated catheterisation 
and filling cystometry probably irritated the LUT of the subjects and might have temporarily 
altered the ACh-release or ACh-sensitivity in the LUT. Tolterodine might have antagonized 
this irritation and thereby kept the filling sensations on a steady level at FDV in group B and 
C and at SDV in group C. 
The ACh-release in the unaffected LUT of a healthy person during storage, which is supposed 
to be quite low, might not be affected by antimuscarinic drugs below a certain dosage. High 
dosage antimuscarinic treatment as used in the study of Stahl et al. might cause further 
depression of ACh-interactions in the LUT of healthy subjects, but usually with the 
disadvantage of impaired bladder emptying (Stahl et al., 1995). 
As our results of the uroflow parameters and PVRV show, tolterodine ER 4 and 8 mg have 
little to no effect on bladder emptying in the healthy subjects, although a slight tendency 
towards higher PVRVs in the tolterodine groups (4 mg < 8 mg) could be observed (Table 1). 
This finding is probably due to the inability of the used tolterodine dosage and formulation to 
block the strong parasympathetic output to the detrusor in healthy subjects. Higher doses of 
tolterodine ER (> 12.8 mg) would be more likely to result in urinary retention (Brynne et al., 
1997). 
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In general, we can not completely exclude that some subjects might have metabolized 
tolterodine differently to other subjects and did not reach the maximum plasma level around 
the assumed 4 hours and therefore might have influenced our findings. However, only a minor 
proportion of the population (e.g. 7% of Caucasians) lack CYP2D6, which is the liver enzyme 
mainly metabolizing tolterodine (Olsson and Szamosi, 2001b). In these ‘poor metabolisers’ 
serum concentrations of tolterodine are higher than in those who possess the enzyme 
(‘extensivemetabolisers’). Nevertheless, despite differences in tolterodine pharmacokinetics, 
exposure to the pharmacologically active moiety in extensive (sum of unbound tolterodine 
and 5-HM) and poor (unbound tolterodine) metabolisers is comparable regardless of 
metabolic phenotype. This is explained by the 10-fold difference in the extent of tolterodine 
and 5-HM binding to serum proteins (unbound fractions of 3.7% and 36%, respectively) 
(Olsson and Szamosi, 2001b). In Addition, the study from Olson and Szamosi demonstrated 
that both, extensive and poor metabolisers show a median tmax of 4 hours (2-6 h in extensive 
metabolisers, 3-6 h in poor metabolisers). Due to its quite stable Cmax over time compared to 
the IR form, the ER form has lower fluctuation index values (Olsson and Szamosi, 2001a). 
Furthermore, due to the randomization, a possible influence of extensive or poor metabolism 
should have been minimized. 
Although we worked as sterile as possible during catheterization, we did not control the urine 
prior to the second measurement and we can not completely exclude a contamination of the 
bladder with bacteria. It might be possible that in some subjects infection was introduced at 
the first catheterization and that with a mean doubling time of 50 min for common bacteria an 
infection could have been present subclinical, which might have added to the sensitization or 
irritation. However, in the follow-up interview 2-3 days later, none of the subjects reported 
about symptoms suggesting lower urinary tract infection like burning sensation during 
micturition, frequency or haematuria. Thus, if a UTI occurred, it was subclinical and self 
limited. 
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Conclusion: 
This prospective urodynamic study shows that a single dose tolterodine extended release 4 
and 8 mg does not increase the filling perception threshold in healthy female subjects. 
However, tolterodine seems to alleviate irritating symptoms caused by the repeated 
catheterisation and filling cystometry, resulting in almost unchanged filling volumes in the 8 
mg group compared to the placebo group, which showed a significant decrease in filling 
volumes at FDV and SDV during repeated cystometry. Tolterodine 4 mg showed a lesser and 
only insignificant effect compared to 8 mg. These effects of tolterodine occurred in the 
absence of a significant change in voiding function. 
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Tables: 
 
Table 1: Mean values ± standard deviation (SD) of age, body mass index (BMI), bladder 
volumes and intravesical pressure at first sensation of filling (FSF), first desire to void (FDV), 
and strong desire to void (SDV), bladder compliance, maximum flow rate during micturition 
(FLOWmax), average flow rate during micturition (FLOWave), and post void residual volume 
(PVRV) for all groups at baseline (BL) and post treatment (PT). 
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Figures: 
 
Fig. 1: Bladder volumes of all 30 subjects at first sensation of filing (FSF), first desire to void 
(FDV), and strong desire to void (SDV) during the baseline cystometry. The boxplots include 
minimum, 25% percentile, median, 75% percentile and maximum. 
 
 
Fig. 2: The diagram shows the bladder volumes at first sensation of filling (FSF) in each 
group before (white box plots) and after (grey box plots) treatment. The boxplots include 
minimum, 25% percentile, median, 75% percentile and maximum. 
 
 
Fig. 3: The diagram shows the bladder volumes at first desire to void (FDV) in each group 
before (white box plots) and after (grey box plots) treatment. The boxplots include minimum, 
25% percentile, median, 75% percentile and maximum. #: p = 0.028 
 
 
Fig. 4: The diagram shows the bladder volumes at strong desire to void (SDV) in each group 
before (white box plots) and after (grey box plots) treatment. The boxplots include minimum, 
25% percentile, median, 75% percentile and maximum. 
#: p = 0.005, *: p = 0.047, §: p = 0.019 
 
 
 
 
Group A 
n = 10 subjects 
Group B 
n = 10 subjects 
Group C 
n = 10 subjects  
Mean SD Mean SD Mean SD 
Age [years]  23.3 2.1 24.6 2.7 23.2 2.1 
BMI [kg/m2]  20.5 1.0 20.4 2.5 20.6 1.4 
BL 147.80 90.58 172.19 78.02 135.95 101.88 
PT 120.95 41.99 173.78 107.46 162.63 120.11 Bladder 
volume at 
FSF [ml] Asymp. 
Sig. 
(2-tailed)  
none  none  none  
BL 298.41 119.51 354.67 156.39 274.04 149.02 
PT 236.77 60.84 314.39 136.42 331.18 147.80 Bladder 
volume at 
FDV [ml] Asymp. 
Sig. 
(2-tailed)  
p = 0.028  none  none  
BL 628.70 141.18 686.50 228.48 625.30 216.50 
PT 414.30 76.35 583.50 239.31 576.90 153.73 Bladder 
volume at 
SDV [ml] Asymp. 
Sig. 
(2-tailed)  
p = 0.005  p = 0.047  none  
BL 3.85 3.07 3.67 4.52 6.18 8.33 
PT 3.76 2.96 3.85 2.44 4.54 2.47 
Intravesical 
pressure at 
FSF 
[cmH2O] 
Asymp. 
Sig. 
(2-tailed)  
none  none  none  
BL 6.20 3.39 6.48 5.12 9.01 10.47 
PT 5.12 3.06 5.55 2.87 7.10 3.44 
Intravesical 
pressure at 
FDV 
[cmH2O] 
Asymp. 
Sig. 
(2-tailed)  
p = 0.047  none  none  
BL 12.12 3.19 9.11 6.09 17.92 20.64 
PT 7.70 3.59 9.04 3.15 11.11 5.50 
Intravesical 
pressure at 
SDV 
[cmH2O] 
Asymp. 
Sig. 
(2-tailed)  
p = 0.005  none  none  
BL 55.9 22.2 123.7 132.5 71.0 72.0 
PT 69.8 39.3 67.7 29.9 60.1 20.5 Compliance 
[ml/cmH2O] Asymp. 
Sig. 
(2-tailed)  
none  none  none  
BL 34.10 15.07 42.50 16.67 41.40 19.29 
PT 33.90 21.55 37.00 17.49 40.22 21.79 Flowmax 
[ml/s] 
Asymp. 
Sig. 
(2-tailed)  
none  none  none  
BL 16.40 7.21 22.50 12.34 21.80 12.60 
PT 14.80 9.38 18.10 8.35 19.60 11.08 Flowave 
[ml/s] 
Asymp. 
Sig. 
(2-tailed)  
none  none  none  
BL 4.10 4.25 4.80 8.01 9.80 19.04 
PT 3.70 4.35 29.10 61.33 18.00 19.17 
PVRV [ml] 
Asymp. 
Sig. 
(2-tailed)  
none  none  none  
 




